4.18

6.28% -0.28

After Hours: 4.44 0.26 +6.22%

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $4.18, with a volume of 920.16K. It is down -6.28% in the last 24 hours and up +2.45% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Previous Close:

$4.46

Open:

$4.41

24h Volume:

920.16K

Relative Volume:

1.08

Market Cap:

$470.25M

Revenue:

$69.56M

Net Income/Loss:

$-240.05M

P/E Ratio:

-1.4169

EPS:

-2.95

Net Cash Flow:

$-121.90M

1W Performance:

-2.56%

1M Performance:

+2.45%

6M Performance:

+190.28%

1Y Performance:

+41.69%

1-Day Range:

$4.07

$4.43

1-Week Range:

$4.07

$4.80

52-Week Range:

$1.05

$4.80

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1136)

Industry

Biotechnology (633)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

263

Twitter

Next Earnings Date

2025-03-21

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	4.18	501.75M	69.56M	-240.05M	-121.90M	-2.95
VRTX Vertex Pharmaceuticals Inc	426.00	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	642.25	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.07	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	826.28	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.23	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

Nov 03, 2025

Will ADC Therapeutics SA Common Shares stock boost dividends furtherWeekly Trade Analysis & Verified Momentum Watchlists - newser.com

Nov 03, 2025

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 - Barchart.com

Nov 03, 2025

Using AI based signals to follow ADC Therapeutics SA2025 Key Highlights & Low Risk Investment Opportunities - newser.com

Nov 03, 2025

What insider trading reveals about ADC Therapeutics SA stockTrade Risk Assessment & Accurate Technical Buy Alerts - newser.com

Nov 03, 2025

Is ADC Therapeutics SA stock attractive for long term wealth buildingEarnings Performance Report & AI Driven Stock Movement Reports - newser.com

Nov 03, 2025

What earnings revisions data tells us about ADC Therapeutics SAVolume Spike & Weekly Watchlist for Hot Stocks - newser.com

Nov 03, 2025

ADC Therapeutics (NYSE: ADCT) to host results call Nov. 10 with live webcast - Stock Titan

Nov 03, 2025

ADC Therapeutics SA stock chart pattern explainedJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - newser.com

Nov 03, 2025

Is it time to cut losses on ADC Therapeutics SAWeekly Loss Report & AI Driven Price Predictions - newser.com

Nov 03, 2025

Is ADC Therapeutics SA Common Shares stock trading at attractive multiples2025 Market Overview & Fast Exit/Entry Strategy Plans - newser.com

Nov 03, 2025

Is ADC Therapeutics SA stock dividend yield sustainableJuly 2025 Gainers & Technical Entry and Exit Tips - newser.com

Nov 03, 2025

Nov 02, 2025

Momentum divergence signals in ADC Therapeutics SA chartStop Loss & Real-Time Volume Surge Alerts - newser.com

Nov 02, 2025

Will ADC Therapeutics SA Common Shares stock beat Nasdaq index returns2025 Major Catalysts & Real-Time Stock Entry Alerts - newser.com

Nov 02, 2025

ADC Therapeutics SA stock outlook for YEARJuly 2025 Breakouts & Daily Technical Stock Forecast Reports - newser.com

Nov 02, 2025

How institutional ownership impacts ADC Therapeutics SA stock2025 Short Interest & Long-Term Safe Investment Plans - newser.com

Nov 02, 2025

ADC Therapeutics SA Hits New 52-Week High of $4.80 - Markets Mojo

Nov 02, 2025

Why retail traders accumulate ADC Therapeutics SA Common Shares stockWeekly Stock Recap & Weekly High Return Forecasts - newser.com

Nov 02, 2025

Is ADC Therapeutics SA stock a top pick in earnings seasonSwing Trade & Reliable Trade Execution Plans - newser.com

Nov 02, 2025